Modality
siRNA
MOA
SOS1i
Target
JAK2
Pathway
Epigenetic
WMCSUSCLC
Development Pipeline
Preclinical
~Nov 2011
→ ~Feb 2013
Phase 1
~May 2013
→ ~Aug 2014
Phase 2
~Nov 2014
→ ~Feb 2016
Phase 3
~May 2016
→ ~Aug 2017
NDA/BLA
Nov 2017
→ Nov 2030
NDA/BLACurrent
NCT06014281
2,763 pts·CSU
2017-11→TBD·Not yet recruiting
NCT04100901
1,612 pts·SCLC
2018-02→2030-11·Terminated
4,375 total pts2 indications
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-11-134.6y awayPh3 Readout· SCLC
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
NDA/BLA
Not yet…
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2030-11-13 · 4.6y away
SCLC
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06014281 | NDA/BLA | CSU | Not yet recr... | 2763 | CfB |
| NCT04100901 | NDA/BLA | SCLC | Terminated | 1612 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| HAL-1232 | Halozyme | Approved | C5 |